We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Fusion Pharmaceuticals Inc | NASDAQ:FUSN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 21.55 | 21.67 | 20.71 | 0 | 01:00:00 |
From Dec 2023 to Jun 2024
By Ben Glickman
Shares of Fusion Pharmaceuticals rose in post-market trading on Thursday after the company had a study protocol approved by regulators.
The stock was up 7.8% to $9.10, after it closed the market session up 6.8%. Shares have more than doubled in the last three months.
The company, which is focused on the development of oncology drugs, said it had aligned with the Food and Drug Administration on its Phase 2/3 protocol for FPI-2265, a treatment for certain kinds of prostate cancer. The updated development plan includes a Phase 2 dose optimization lead-in and a Phase 3 registrational trial, which is expected to begin in 2025.
The treatment is a targeted alpha therapy that will be evaluated for use in patients with metastatic castration-resistant prostate cancer with progressive disease.
Chief Executive John Valliant said the plan outlined a path for bringing the therapy to market, if approved.
Fusion said it had also produced its first clinical dose at its proprietary manufacturing facility.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
January 04, 2024 18:38 ET (23:38 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
1 Year Fusion Pharmaceuticals Chart |
1 Month Fusion Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
